CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性淋巴瘤患者 CD19 CAR-T 治疗后继发性骨髓增生异常综合征
英文原题：Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.
查看英文原题
Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
该病例展示了 R/R B 细胞淋巴瘤患者在接受 CD19 CAR-T 治疗后 SMN 的发生和进展，并为此种不常见的后期事件提供了有用信息。
研究思路结论见上方概要
背景
尽管几种靶向CD19的CAR-T 细胞可治愈复发/难治性（R/R）B细胞淋巴瘤患者，但该CAR-T 疗法的临床安全性和有效性仍不明确。在CAR-T 疗法中，继发性恶性肿瘤的风险，尤其是髓系肿瘤，尤其令人担忧。
方法
一名R/R滤泡性淋巴瘤患者在接受CD19 CAR-T 治疗后被诊断为继发性骨髓增生异常综合征（s-MDS）。我们还对近期发表的关于CAR-T 治疗后继发性髓系肿瘤（SMN）风险的文献进行了综述。
结果
患者在接受CD19 CAR-T 治疗后出现继发性MDS。她接受了近一年的积极治疗，之后死亡。
展开英文摘要原文
BACKGROUND
Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and ef cacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.
METHODS
A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.
RESULTS
The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.
CONCLUSIONS
The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.
论文信息
- 作者
- Lu C、Zhao MZ
- 文献类型
- 病例报告 · 综述
- 期刊
- Clinical laboratory2025 Feb 1
- 原文标识
- PubMed 39967542 · DOI 10.7754/Clin.Lab.2024.240910